Live Breaking News & Updates on T Dm1 Plus Or Minus Tucatinib

Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape. ....

United States , Dana Farber Cancer Institute , Adrienneg Waks , Clinical Research At Dana Farber Cancer Institute , Harvard Medical School , Clinical Research , Patients With Her2 Positive Breast Cancer , Adjuvant Trastuzumab Emtansine , Neoadjuvant Paclitaxel , Nd Pertuzumab , T Dm1 Plus Or Minus Tucatinib , T Dm1 Vs Trastuzumab Deruxtecan , Immune Checkpoint Blockade In Her2 Positive Disease , Her2climb 04 , Her2climb 02 , Brain Metastases , Antibody Drug Conjugate ,